キメラ抗原受容体（CAR）T細胞療法の世界市場は、2021年の15億ドルから、2026年までに76億ドルに達し、2021年から2026年までのCAGRは39.1％と予想されます。
目次
Chapter- 1: Introduction
Scope of This Report
What's New in this Update?
Methodology and Information Sources
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter- 2: Summary and Highlights
CAR T-Cell Design and Evolution
FDA Product Approvals
Market Analysis
Clinical Applications of CAR T-Cell Therapy
Barriers to Research and Product Development
Clinical Trials
Chapter- 3: Introduction to Chimeric Antigen Receptor (CAR) T-Cell Therapy
Introduction
A Brief History of CAR T-Cell Therapy Development
Antigens
Cluster of Differentiation
Lymphocytes
Adoptive Cell Transfer (ACT) Technologies
Chapter- 4: Impact of COVID-19 on the Market
Overview
Chapter- 5: Market Dynamics
Market Dynamics
Chapter- 6: Current Production Methods, Latest Technological Advances and Future Direction
Production of CAR T Cells
Overcoming CAR T-Cell Manufacturing Challenges
Latest Advances in Production Processes
Chapter- 7: Clinical Trials on CAR T Cells and Related Technologies
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Trials in the U.S.
Distribution of CAR T-Cell Clinical Trials in China
Chapter- 8: Cancer Demographics: A Global Summary
Cancer: The Disease
Epidemiology by Cancer Type/Site
Cancer Epidemiology by Region
Global Cancer Burden and Worldwide Cancer Risk Factors
Chapter- 9: Global CAR T-Cell Market Analysis
Introduction
Global CAR T-Cell Market
Chapter- 10: Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Table 28 : Global CAR T-Cell Market, by Region, Through 2026
Table 29 : Global CAR T-Cell Market Share, by Region, 2021
Figure 36 : Global CAR T-Cell Market Share, by Region, 2021
Chapter- 11: Regulatory and Legislative Requirements
North America
Europe
Asia-Pacific
Central and South America
Middle East and Africa
Published Guidelines on Production and Testing of Cell-Based Therapies
Chapter- 12: Patent Review/New Developments
Introduction
Company Specific Intellectual Property and Patent Information
Chapter- 13: Global Competitive Market Landscape
Global CAR T-Cell Market Share Analysis
Product Launches
Strategic Initiatives
Mergers and Acquisitions
Chapter- 14: Company Profiles
ABBVIE INC.
AMGEN
ASTRAZENECA
AVACTA LIFE SCIENCES LTD.
BELLICUM PHAMACEUTICALS
BLUEBIRD BIO
BRISTOL MYERS SQUIBB
CELLECTIS
CELYAD SA
EDITAS MEDICINE INC.
EUREKA THERAPEUTICS INC.
FORMULA PHARMACEUTICALS INC.
GILEAD SCIENCES
F. HOFFMAN-LA ROCHE AG
ICELL GENE THERAPEUTICS
MUSTANG BIO INC.
NOILE-IMMUNE BIOTECH
NOVARTIS AG
PROTHERAGEN INC.
PURETECH HEALTH
SERVIER LABORATORIES
TAKEDA PHARMACEUTICALS
TRANSGENE SA
Chapter- 15: Appendix A
Company Contact Details
Chapter- 16: Appendix B
Government Regulatory Agencies and Professional Organizations
Chapter- 17: Appendix C
Commonly Used Acronyms Associated with CAR T-Cell Therapy
Chapter- 18: Appendix D
Recent Patent Applications Filed Related to CAR T-Cell Therapy
Chapter- 19: Appendix E
CAR T-Cell and CD19 Clinical Trials in China
